Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Rating of “Strong Buy” from Brokerages

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been given an average broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company. Aeglea Bio Therapeutics’ rating score has declined by 33% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus price objective of $18.00 for the company and are forecasting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 178 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Several equities analysts have weighed in on AGLE shares. Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. BMO Capital Markets restated an “outperform” rating and set a $18.00 price objective on shares of Aeglea Bio Therapeutics in a research note on Wednesday, March 14th. Finally, Needham & Company LLC raised their price objective on Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, March 14th.



Shares of NASDAQ:AGLE opened at $9.62 on Monday. Aeglea Bio Therapeutics has a 1-year low of $2.81 and a 1-year high of $11.35. The firm has a market cap of $160.81, a price-to-earnings ratio of -5.34 and a beta of -0.20.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings data on Tuesday, March 13th. The biotechnology company reported ($0.38) earnings per share for the quarter. Aeglea Bio Therapeutics had a negative net margin of 523.37% and a negative return on equity of 48.29%. The company had revenue of $1.48 million for the quarter. equities research analysts anticipate that Aeglea Bio Therapeutics will post -1.93 earnings per share for the current year.

A number of large investors have recently modified their holdings of the business. Jennison Associates LLC raised its stake in shares of Aeglea Bio Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after purchasing an additional 8,372 shares during the period. Vanguard Group Inc. raised its stake in shares of Aeglea Bio Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after purchasing an additional 12,966 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Aeglea Bio Therapeutics by 150.8% during the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 19,300 shares during the period. Institutional investors and hedge funds own 47.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Rating of “Strong Buy” from Brokerages” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/16/aeglea-bio-therapeutics-inc-agle-receives-consensus-rating-of-strong-buy-from-brokerages.html.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply